Moreover, the oncogene NRAS was among the n-Myc/c-Myc co-targets and interacted with other HR-NB-causing mutations, such as ALK, TP53 and BARD1. Notably, RAS mutation or activation has been reported to enhance MYC oncogenicity (reviewed by34). This evidence concerns the gene MYC and neuroblastoma.